Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
| Autor: | Anjela Galan, William Damsky, Nkiruka Emeagwali, Brett A. King, Durga Thakral |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Sarcoidosis Cutaneous Sarcoidosis Disease Skin Diseases Article Lesion Pathogenesis 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Piperidines Sarcoidosis Pulmonary medicine Humans Pyrroles Protein Kinase Inhibitors Janus Kinases Skin Tofacitinib Sequence Analysis RNA business.industry Remission Induction General Medicine Middle Aged medicine.disease Immunohistochemistry Dermatology STAT Transcription Factors Pyrimidines 030228 respiratory system Female medicine.symptom business Janus kinase Signal Transduction |
| Zdroj: | New England Journal of Medicine. 379:2540-2546 |
| ISSN: | 1533-4406 0028-4793 |
| Popis: | There is evidence that Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling plays a role in the pathogenesis of sarcoidosis. We treated a patient with cutaneous sarcoidosis with the JAK inhibitor tofacitinib; the patient had not previously had a response to medications and had not received systemic glucocorticoids. This treatment resulted in clinical and histologic remission of her skin disease. Sequencing of RNA and immunohistochemical examination of skin-lesion samples obtained from the patient before and during therapy and immunohistochemical testing of lesion samples obtained from other patients with cutaneous sarcoidosis support a role for JAK-STAT signaling in cutaneous sarcoidosis. (Funded by the Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research and others.). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|